NATCO Pharma Ltd receives 7 Observations from USFDA for API unit at Manali, Chennai

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced conclusion of US FDA Inspection at our Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit.

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Manali, Chennai, India, which was conducted from November 17th - November 21st, 2025.

On conclusion of the inspection, the Company received seven observations in the Form-483. The Company believes that the observations are procedural in nature. The Company is confident to address these observations comprehensively.

Company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 864.40 as compared to the previous close of Rs. 869.30. The total number of shares traded during the day was 67476 in over 3983 trades.

The stock hit an intraday high of Rs. 872.05 and intraday low of 857.00. The net turnover during the day was Rs. 58304584.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals USFDA Inspection 7Observations APIUnit Manali Chennai